Development of IFNβ-1a versions with reduced immunogenicity and full in vitro biological activity for the treatment of multiple sclerosis

Development of IFNβ-1a versions with reduced immunogenicity and full in vitro biological activity for the treatment of multiple sclerosis

Copyright © 2023 Elsevier Inc. All rights reserved.

Bibliographische Detailangaben
Veröffentlicht in:Clinical immunology (Orlando, Fla.). - 1999. - 257(2023) vom: 05. Dez., Seite 109831
1. Verfasser: Ricotti, Sonia (VerfasserIn)
Weitere Verfasser: Garay, Alberto Sergio, Etcheverrigaray, Marina, Amadeo, Gabriel Ignacio, De Groot, Anne S, Martin, William, Mufarrege, Eduardo Federico
Format: Online-Aufsatz
Sprache:English
Veröffentlicht: 2023
Zugriff auf das übergeordnete Werk:Clinical immunology (Orlando, Fla.)
Schlagworte:Journal Article Research Support, Non-U.S. Gov't De-immunization EpiMatrix Human anti-viral therapy IFNβ Immunogenicity In vivo assays Multiple sclerosis Neutralizing antibodies mehr... Transgenic mice Interferon-beta 77238-31-4 Interferon beta-1a XRO4566Q4R Adjuvants, Immunologic
Online verfügbar Volltext